0
Poster Presentations: Wednesday, October 26, 2011 |

Aclidinium Bromide in Patients With Chronic Obstructive Pulmonary Disease: Improvement in Symptoms and Health Status in the ATTAIN Study FREE TO VIEW

Paul Jones, MD; Alvar Agusti, MD; Eric Bateman, MD; David Singh, MD; Rosa Lamarca, PhD; Gonzalo de Miquel, MD; Cynthia Caracta, MD; Esther Garcia Gil, MD
Chest. 2011;140(4_MeetingAbstracts):547A. doi:10.1378/chest.1119097
Text Size: A A A
Published online

Abstract

PURPOSE: ATTAIN investigated the efficacy and safety of twice-daily aclidinium bromide (200 and 400 µg), a long-acting muscarinic antagonist, on symptoms and health status in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).

METHODS: In this 24-week, double-blind, Phase III study (NCT01001494), patients were randomized (1:1:1) to aclidinium 200, 400 µg or placebo, twice-daily. Dyspnea was assessed using the Transitional Dyspnea Index (TDI), and symptoms by daily electronic diaries using the EXACT Respiratory Symptoms (E-RS) scores, and a night-time and early-morning symptoms questionnaire. Health status was assessed using the St George’s Respiratory Questionnaire (SGRQ).

RESULTS: In total 828 patients were randomized. At Week 24, more patients treated with aclidinium (200, 400 µg) reached a clinically relevant improvement in TDI focal score (≥1 unit) vs placebo (53.3% and 56.9% vs 45.5%; p=0.032 and 0.004, respectively). Aclidinium significantly reduced E-RS scores vs placebo: RS-breathlessness (range 0-17) (200 µg, -0.8 [p≤0.0001]; 400 µg, -1.05 [p≤0.0001]); RS-chest (range 0-12) (200 µg, -0.33 [p≤0.003]; 400 µg, -0.52 [p≤0.0001]); and RS-cough and sputum (range 0-11) (200 µg, -0.21 [p≤0.03]; 400 µg, -0.44 [p≤0.0001]) at Week 24. Aclidinium reduced the incidence of night-time (p<0.001) and early-morning (p<0.01) symptoms and was associated with more days without reliever medication (p=0.0003), vs placebo. At Week 24, more patients had a clinically relevant improvement in SGRQ total score with aclidinium 200 and 400 µg vs placebo (54.9% and 54.3% vs 39.5%; p=0.0004 and 0.0014, respectively); the improvement with aclidinium 400 µg vs placebo was 4.3 units, p<0.0001. SGRQ domain scores (Symptoms, Activity, Impacts) were also significantly improved with aclidinium (200, 400 µg) vs placebo at Week 24 (p<0.05 all domains).

CONCLUSIONS: Aclidinium 200 and 400 µg BID provided statistically significant and clinically relevant improvements in COPD symptoms and health status in patients with COPD.

CLINICAL IMPLICATIONS: These results indicate that aclidinium could be a valuable new treatment option for COPD. This study was supported by Almirall S.A., Barcelona, Spain, and Forest Laboratories, Inc, New York, USA.

DISCLOSURE: Paul Jones: Consultant fee, speaker bureau, advisory committee, etc.: Consultancy fees charged through my University

Alvar Agusti: Other: Member of advisory boards, grant support and funding for accommodation and travel from Almirall

Eric Bateman: Grant monies (from industry related sources): Institution for clinical trial participation (not to self), Consultant fee, speaker bureau, advisory committee, etc.: Advisory board and consultancy payments from Almirall and Forest

David Singh: Other: Lecture fees, research grants, consultancy fees and support for conference attendance from various pharmaceutical companies including AstraZeneca, GlaxoSmithKline, Chiesi, Boehringer Ingelheim and Roche

Rosa Lamarca: Employee: Almirall

Gonzalo de Miquel: Employee: Almirall

Cynthia Caracta: Employee: Forest Research Institute

Esther Garcia Gil: Employee: Almirall

Aclidinium bromide is a long-acting anti-muscarinic agent, property of Almirall S.A., which is being developed for the treatment of COPD. Aclidinium is not yet approved and the current presetnation is about clinical trial results with this compound under research.

09:00 AM - 10:00 AM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543